|30 OCTOBER 2013|
Life Length announced today that Dr. Takuji Shirawawa has joined its Scientific Advisory Board. Dr. Takuji Shirasawa is one of Japan’s leading scientists. He is the Professor of Aging Control Medicine at Juntendo University, Graduate School of Medicine in Japan. He obtained his Ph.D. in immunology at Chiba University Graduate School of Medicine and has been researching molecular pathology and the molecular genetics of gerontology for the past 20 years. He is the Director of the Japan Anti-Aging Association, Japan Biogerontology and Biorehabilitation Association. He is the Editor of the Journal of Neuroscience Research.
His research interests include the molecular biology of aging and gerontology, the molecular genetics of Alzheimer’s Disease, and telomere research. He is regarded as one of Japan’s top specialists in preventive medicine for aging and has written over 130 books becoming the most published doctor in Japan. Over 2 million copies of his books have been sold in Japan and many books have been translated and published abroad. Stephen J. Matlin, CEO, Life Length said, “We are delighted to have Dr. Shirasawa join our Scientific Advisory Board.
He brings an enormous wealth of experience in field of telomere biology and its relationship to aging and age-related diseases. His support will also be invaluable as we launch our services in Japan.” Dr. Shirasawa commented, “I am very pleased to join Life Length’s Scientific Advisory Board. Life Length is unquestionably the leading company in the world in telomere measurement and as a scientist and physician working to improve human health and longevity, I feel very strongly that this is a very important biomarker that needs to be adopted in the medical field. Judging from their robust technology and insightful analytical results, Life Length’s TAT test is the gold standard and I am excited to help them bring it to Japan and expand the database of Japanese and eventually, Asian population.”